Nanjing King-Friend Biochemical PharmaceuticalLtd Past Earnings Performance
Past criteria checks 0/6
Nanjing King-Friend Biochemical PharmaceuticalLtd's earnings have been declining at an average annual rate of -18.3%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 9.6% per year.
Key information
-18.3%
Earnings growth rate
-18.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 9.6% |
| Return on equity | -6.7% |
| Net Margin | -10.9% |
| Next Earnings Update | 29 Apr 2025 |
Recent past performance updates
Recent updates
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.'s (SHSE:603707) Popularity With Investors Is Under Threat From Overpricing
Nov 27
Would Nanjing King-Friend Biochemical PharmaceuticalLtd (SHSE:603707) Be Better Off With Less Debt?
Sep 30Investors Still Waiting For A Pull Back In Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHSE:603707)
Aug 26Nanjing King-Friend Biochemical PharmaceuticalLtd (SHSE:603707) Is Making Moderate Use Of Debt
Jun 26Getting In Cheap On Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHSE:603707) Might Be Difficult
May 26Revenue & Expenses Breakdown
How Nanjing King-Friend Biochemical PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 3,877 | -423 | 472 | 376 |
| 30 Jun 24 | 3,770 | -409 | 467 | 396 |
| 31 Mar 24 | 3,628 | -345 | 510 | 380 |
| 31 Dec 23 | 3,931 | -189 | 563 | 372 |
| 30 Sep 23 | 4,004 | 1,023 | 581 | 315 |
| 30 Jun 23 | 4,041 | 1,101 | 674 | 309 |
| 31 Mar 23 | 3,844 | 1,093 | 643 | 278 |
| 31 Dec 22 | 3,713 | 1,091 | 618 | 264 |
| 30 Sep 22 | 3,758 | 1,122 | 591 | 229 |
| 30 Jun 22 | 3,911 | 1,118 | 610 | 231 |
| 31 Mar 22 | 3,980 | 1,116 | 596 | 241 |
| 31 Dec 21 | 3,687 | 1,059 | 608 | 221 |
| 30 Sep 21 | 3,537 | 1,038 | 600 | 197 |
| 30 Jun 21 | 3,270 | 953 | 570 | 188 |
| 31 Mar 21 | 3,064 | 875 | 588 | 174 |
| 31 Dec 20 | 2,915 | 806 | 559 | 188 |
| 30 Sep 20 | 2,800 | 770 | 541 | 189 |
| 30 Jun 20 | 2,689 | 724 | 497 | 187 |
| 31 Mar 20 | 2,594 | 660 | 466 | 178 |
| 31 Dec 19 | 2,470 | 605 | 422 | 166 |
| 30 Sep 19 | 2,224 | 539 | 418 | 138 |
| 30 Jun 19 | 2,027 | 487 | 371 | 125 |
| 31 Mar 19 | 1,875 | 452 | 320 | 113 |
| 31 Dec 18 | 1,700 | 425 | 284 | 101 |
| 30 Sep 18 | 1,633 | 425 | 206 | 118 |
| 30 Jun 18 | 1,479 | 418 | 131 | 128 |
| 31 Mar 18 | 1,325 | 380 | 103 | 102 |
| 31 Dec 17 | 1,113 | 314 | 94 | 77 |
| 30 Sep 17 | 915 | 276 | 69 | 44 |
| 30 Jun 17 | 758 | 193 | 113 | 0 |
| 31 Mar 17 | 668 | 284 | 127 | 0 |
| 31 Dec 16 | 582 | 257 | 95 | 0 |
| 31 Dec 15 | 469 | 88 | 55 | 0 |
| 31 Dec 14 | 416 | 50 | 43 | 0 |
Quality Earnings: 603707 is currently unprofitable.
Growing Profit Margin: 603707 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603707 is unprofitable, and losses have increased over the past 5 years at a rate of 18.3% per year.
Accelerating Growth: Unable to compare 603707's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 603707 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.5%).
Return on Equity
High ROE: 603707 has a negative Return on Equity (-6.75%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 10:02 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Yong Jian Li | China Merchants Securities Co. Ltd. |
| Shitong Han | Citic Securities Co., Ltd. |